171 related articles for article (PubMed ID: 19589464)
1. A family with paroxysmal nonkinesigenic dyskinesia: genetic and treatment issues.
Szczałuba K; Jurek M; Szczepanik E; Friedman A; Milewski M; Bal J; Mazurczak T
Pediatr Neurol; 2009 Aug; 41(2):135-8. PubMed ID: 19589464
[TBL] [Abstract][Full Text] [Related]
2. Genotype-phenotype correlation of paroxysmal nonkinesigenic dyskinesia.
Bruno MK; Lee HY; Auburger GW; Friedman A; Nielsen JE; Lang AE; Bertini E; Van Bogaert P; Averyanov Y; Hallett M; Gwinn-Hardy K; Sorenson B; Pandolfo M; Kwiecinski H; Servidei S; Fu YH; Ptácek L
Neurology; 2007 May; 68(21):1782-9. PubMed ID: 17515540
[TBL] [Abstract][Full Text] [Related]
3. Familial paroxysmal nonkinesigenic dyskinesia: clinical and genetic analysis of a Taiwanese family.
Yeh TH; Lin JJ; Lai SC; Wu-Chou YH; Chen AC; Yueh KC; Chen RS; Lu CS
J Neurol Sci; 2012 Dec; 323(1-2):80-4. PubMed ID: 22967746
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics of paroxysmal nonkinesigenic dyskinesia in Serbian family with Myofibrillogenesis regulator 1 gene mutation.
Stefanova E; Djarmati A; Momcilović D; Dragasević N; Svetel M; Klein C; Kostić VS
Mov Disord; 2006 Nov; 21(11):2010-5. PubMed ID: 16972263
[TBL] [Abstract][Full Text] [Related]
5. Genetic heterogeneity in paroxysmal nonkinesigenic dyskinesia.
Spacey SD; Adams PJ; Lam PC; Materek LA; Stoessl AJ; Snutch TP; Hsiung GY
Neurology; 2006 May; 66(10):1588-90. PubMed ID: 16717228
[TBL] [Abstract][Full Text] [Related]
6. Presence of alanine-to-valine substitutions in myofibrillogenesis regulator 1 in paroxysmal nonkinesigenic dyskinesia: confirmation in 2 kindreds.
Chen DH; Matsushita M; Rainier S; Meaney B; Tisch L; Feleke A; Wolff J; Lipe H; Fink J; Bird TD; Raskind WH
Arch Neurol; 2005 Apr; 62(4):597-600. PubMed ID: 15824259
[TBL] [Abstract][Full Text] [Related]
7. Levetiracetam in the treatment of paroxysmal kinesiogenic choreoathetosis.
Chatterjee A; Louis ED; Frucht S
Mov Disord; 2002 May; 17(3):614-5. PubMed ID: 12112221
[TBL] [Abstract][Full Text] [Related]
8. Sublingual lorazepam in the treatment of familial paroxysmal nonkinesigenic dyskinesia.
Dooley JM; Brna PM
Pediatr Neurol; 2004 May; 30(5):365-6. PubMed ID: 15165643
[TBL] [Abstract][Full Text] [Related]
9. Levetiracetam-responding paroxysmal nonkinesigenic dyskinesia.
Alemdar M; Iseri P; Selekler M; Komsuoğlu SS
Clin Neuropharmacol; 2007; 30(4):241-4. PubMed ID: 17762321
[TBL] [Abstract][Full Text] [Related]
10. Paroxysmal kinesigenic dyskinesia and generalized seizures: clinical and genetic analysis in a Spanish pedigree.
Cuenca-Leon E; Cormand B; Thomson T; Macaya A
Neuropediatrics; 2002 Dec; 33(6):288-93. PubMed ID: 12571782
[TBL] [Abstract][Full Text] [Related]
11. Myofibrillogenesis regulator 1 gene (MR-1) mutation in an Omani family with paroxysmal nonkinesigenic dyskinesia.
Hempelmann A; Kumar S; Muralitharan S; Sander T
Neurosci Lett; 2006 Jul; 402(1-2):118-20. PubMed ID: 16632198
[TBL] [Abstract][Full Text] [Related]
12. A case of familial paroxysmal nonkinesigenic dyskinesia due to mutation of the PNKD gene in Chinese Mainland.
Liang S; Yu X; Zhang S; Tai J
Brain Res; 2015 Jan; 1595():120-6. PubMed ID: 25107857
[TBL] [Abstract][Full Text] [Related]
13. Levetiracetam therapy for treatment of choreoathetosis in dyskinetic cerebral palsy.
Vles GF; Hendriksen JG; Visschers A; Speth L; Nicolai J; Vles JS
Dev Med Child Neurol; 2009 Jun; 51(6):487-90. PubMed ID: 19018837
[TBL] [Abstract][Full Text] [Related]
14. Effective Treatment of Paroxysmal Nonkinesigenic Dyskinesia With Oxcarbazepine.
Kumar A; Szekely A; Jabbari B
Clin Neuropharmacol; 2016; 39(4):201-5. PubMed ID: 27046658
[TBL] [Abstract][Full Text] [Related]
15. Chorea in a patient with cerebral palsy: treatment with levetiracetam.
Recio MV; Hauser RA; Louis ED; Radhashakar H; Sullivan KL; Zesiewicz TA
Mov Disord; 2005 Jun; 20(6):762-4. PubMed ID: 15747368
[TBL] [Abstract][Full Text] [Related]
16. Paroxysmal non-kinesigenic dyskinesia caused by the mutation of MR-1 in a large Polish kindred.
Friedman A; Zakrzewska-Pniewska B; Domitrz I; Lee HY; Ptacek L; Kwiecinski H
Eur Neurol; 2009; 61(1):39-41. PubMed ID: 18948699
[TBL] [Abstract][Full Text] [Related]
17. Clinical and polygraphic study of familial paroxysmal kinesigenic dyskinesia with PRRT2 mutation.
Fabbri M; Marini C; Bisulli F; Di Vito L; Elia A; Guerrini R; Mei D; Tinuper P
Epileptic Disord; 2013 Jun; 15(2):123-7. PubMed ID: 23771590
[TBL] [Abstract][Full Text] [Related]
18. Paroxysmal non-kinesigenic dyskinesia due to a PNKD recurrent mutation: report of two Southern European families.
Pons R; Cuenca-León E; Miravet E; Pons M; Xaidara A; Youroukos S; Macaya A
Eur J Paediatr Neurol; 2012 Jan; 16(1):86-9. PubMed ID: 21962874
[TBL] [Abstract][Full Text] [Related]
19. Treatment of tardive dyskinesia with levetiracetam in a transplant patient.
Zivković SA; Costa G; Bond G; Abu-Elmagd KM
Acta Neurol Scand; 2008 May; 117(5):351-3. PubMed ID: 17995990
[TBL] [Abstract][Full Text] [Related]
20. Childhood paroxysmal kinesigenic dyskinesia: report of seven cases with onset at an early age.
Li Z; Turner RP; Smith G
Epilepsy Behav; 2005 May; 6(3):435-9. PubMed ID: 15820356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
